InvestorsHub Logo

HMB2010

04/18/19 8:26 AM

#189950 RE: XenaLives #189948

Thank you. Great read.

nidan7500

04/18/19 8:31 AM

#189951 RE: XenaLives #189948

A step in the right direction is represented by the recent formulation of unbiased agnostic biomarker classification systems for AD and neurodegenerative diseases to identify and grade risk in normal elderly people. The goal is to identify the full spectrum of the specific biological alterations in elderly individuals at risk long before the appearance of first clinical symptoms.



A recurring theme w/HH. Blocking and tackling basics.

Penny Double

04/18/19 8:55 AM

#189952 RE: XenaLives #189948

Why use a shotgun when you have a rifle?

Sniper (precision) X ( biomarkers)Mark's the spot!

roygbiv

04/18/19 11:59 AM

#189960 RE: XenaLives #189948

S.Kettering PM gene databse for cancer only considers a small segment of gene mutations(468), via MSK-IMPACT. (not PM, imo)

https://www.mskcc.org/msk-impact


It seems the approach/method below fits the PM bill and would work for many diseases, including CNS.

*Includes whole genome/exome sequencing of 20,000 genes and 3 billion base pairs

*Incorporates whole transcriptome sequencing of over 200,000 RNA transcripts

*Compares a patient’s tumor genome to their normal genome and provides pharmacogenomic analysis for potential drug toxicity and/or interactions

https://nanthealth.com/gps-cancer/


https://clinicaltrials.gov/ct2/show/NCT03073473


Thanks!